Universal HBV vaccination dramatically reduces the prevalence of HBV infection and incidence of hepatocellular carcinoma

Summary Background Universal vaccination of newborns with hepatitis B virus (HBV) vaccine is the most important strategy to prevent chronic HBV infection and its complications of which hepatocellular carcinoma (HCC) as the deadliest. Aims To evaluate the impact of universal HBV vaccination on the pr...

Full description

Saved in:
Bibliographic Details
Published inAlimentary pharmacology & therapeutics Vol. 56; no. 5; pp. 869 - 877
Main Authors Wong, Grace Lai‐Hung, Hui, Vicki Wing‐Ki, Yip, Terry Cheuk‐Fung, Liang, Lilian Yan, Zhang, Xinrong, Tse, Yee‐Kit, Lai, Jimmy Che‐To, Chan, Henry Lik‐Yuen, Wong, Vincent Wai‐Sun
Format Journal Article
LanguageEnglish
Published England Wiley Subscription Services, Inc 01.09.2022
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Summary Background Universal vaccination of newborns with hepatitis B virus (HBV) vaccine is the most important strategy to prevent chronic HBV infection and its complications of which hepatocellular carcinoma (HCC) as the deadliest. Aims To evaluate the impact of universal HBV vaccination on the prevalence of chronic HBV infection, and the incidences of HCC and hepatic events in young adults born before and after the introduction of the universal HBV vaccination programme in 1988 in Hong Kong Methods This was a territory‐wide retrospective observational cohort study of consecutive adult subjects born in 1970–2002 with hepatitis B surface antigen (HBsAg) checked. Subjects born during the vaccination era (1988–2002) were included in the vaccinated cohort; subjects born between 1970 and 1987 were included in the unvaccinated cohort. Results We included 695,925 subjects for HBV prevalence analysis. Chronic HBV infection dropped from 14.3% in subjects born in 1970, to 6.7% in subjects born in 1988. In total, 53,960 vaccinated and 318,290 unvaccinated subjects who had available clinical data were included for event analysis. HCC and hepatic events occurred in 44 (0.1%) and 75 (0.1%) of the vaccinated subjects and in 1305 (0.4%) and 1806 (0.6%) of the unvaccinated subjects, respectively. All incidence rates remained numerically lower in vaccinated subjects after adjustment for age, gender and antiviral treatment, but failed to reach statistical significance due to very low incidence rates. Conclusions Universal HBV vaccination markedly reduces the prevalence of chronic HBV infection and may contribute to the decreased incidences of HCC and hepatic events.
Bibliography:The Handling Editor for this article was Professor Geoffrey Dusheiko, and it was accepted for publication after full peer‐review.
Health and Medical Research Fund (HMRF) of the Food and Health Bureau Commissioned Research on Hepatitis The HKSAR Government (grant number CID‐CUHK‐D).
Financial information
Grace Lai‐Hung Wong and Vicki Wing‐Ki Hui have equal contribution.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
ISSN:0269-2813
1365-2036
1365-2036
DOI:10.1111/apt.17120